9. The vaccine composition of claim 2, wherein the fusion peptide comprises an amino acid sequence that has at least 99% identity to SEQ ID NO: 8 or SEQ ID NO:9.

10. The vaccine composition of claim 6, wherein the fusion peptide consists of an amino acid sequence of SEQ ID NO: 8 or SEQ ID NO:9.

11. The vaccine composition of any one of claims 1 to 10, wherein the carrier protein comprises from 2 to 39 fusion peptides.

12. The vaccine composition of claim 11, wherein the carrier protein comprises from 6 to 12 fusion peptides.

13. The vaccine composition of any one of claims 1 to 12, wherein the adjuvant is selected from the group consisting of aluminium hydroxide, aluminium phosphate, potassium aluminium sulfate, calcium phosphate hydroxide, Freund's complete adjuvant, a water-in-oil emulsion, an oil-in-water emulsion, Freund's incomplete adjuvant, iscoms, iscom matrix, QS-21, a QS-21 derivative, and an adjuvant containing QS-21 or a QS21 derivative.

14. The vaccine composition of claim 13, wherein the adjuvant is aluminium hydroxide.

15. The vaccine composition of claim 13, wherein the adjuvant is a water-in-oil emulsion.

16. The vaccine composition of any one of claims 1 to 15, further comprising a checkpoint inhibitor.

17. A pharmaceutical composition comprising the vaccine composition of any one of claims 1 to 16 and a pharmaceutically acceptable carrier.

18. Use of the vaccine composition of any one of claims 1 to 16 in the manufacture of a medicament for treating or preventing a cancer characterized by expression or over-expression of Her2/neu in a patient in need thereof.

19. Use of claim 18, wherein the cancer is breast cancer.

20. Use of claim 18, wherein the cancer is gastric cancer.

21. The vaccine composition of any one of claims 1 to 16 or the pharmaceutical composition of claim 17 for use in treating or preventing a cancer characterized by expression or over-expression of Her2/neu in a patient in need thereof.

22. The vaccine composition of claim 21, wherein the cancer is breast cancer.

23. The vaccine composition of claim 21, wherein the cancer is gastric cancer.